Refine by
Stemline Drug Administration Equipment & Supplies
1 equipment items found
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
ELZONRISTM (tagraxofusp, SL-401) — ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123), a target present on a wide range of malignancies. ELZONRIS was approved by the US Food and Drug Administration (FDA) on December 21, 2018, for the treatment of adult and pediatric patients, 2 years and older, with blastic ...